Business Wire

Dole, Employees Give to Restore and Rebuild Devastated Central America

Share

On November 3, 2020 Hurricane Eta made landfall in Central America as a powerful Category 4 storm. Just two weeks later Hurricane Iota, a Category 5 storm followed nearly the same path through the region, unleashing heavy rains, winds, massive flooding and severe landslides, causing widespread destruction.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005255/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Replanting bananas in Honduras. Restoring fields and livelihoods destroyed by Hurricanes Eta and Iota in November 2020. (Photo: Business Wire)

Communities and towns in Honduras and Guatemala - many that support Dole farms and workers – were leveled in the wake. Though Dole was able to successfully evacuate its workers and families prior to the hurricanes’ arrivals, many others were not as fortunate and lost their lives or livelihoods, their possessions and their crops. In the aftermath, water was needed to drink, homes were in need of repair, and clothes, supplies and appliances in need of replacement.

As an organization closely connected to these communities through the banana industry, Dole swiftly moved to lend aid and resources. But not just the company as an entity stepped in, many Dole employees, partners, and public supporters —no matter how far physically from these communities — also contributed their own time and their own funds to help.

In these six months since the hurricanes’ devastation much has been accomplished.

  • Dole employees, the company and the public together raised, collected and donated a quarter of a million dollars to purchase food baskets of essential food items -- red beans, rice, corn flour, vegetable oil and powdered milk, capable of feeding a family of five for a month. These food baskets were distributed to 10,000 families in-need in communities surrounding our operations and through relief organizations CEPUDO and the Cortés Chamber of Commerce with established distribution networks in other areas.
  • The Red Cross of Honduras received donations of dozens of boxes of clothing and footwear contributed by Dole employees in North America and Dole’s Standard Fruit De Honduras. In addition to 500,000 Lempiras ($20,000US) to help those in need and provide support.
  • Dole provided use of company machinery and heavy equipment to repair public services, bridges, roads, and highways.
  • Dole allocated space on southbound vessels to humanitarian organizations importing and distributing disaster relief goods and equipment.
  • With many banana production areas completely destroyed, Dole, as a major employer of choice in the region, has expedited efforts to restore banana plantations to full production. Farm land preparation takes time and is completely tailored to the conditions of each agricultural area, yet returning jobs and paychecks to the areas quickly is critical.

“I cannot sufficiently convey the heartbreaking destruction these communities endured,” said Nelson Montoya President of Dole Fresh Fruit North America. “However, this catastrophe did not defeat them. The compassion, resiliency and camaraderie of all those on our team in Honduras and Guatemala has been inspiring to me. We will continue to invest in getting everyone back on their feet.”

The investment reached a significant milestone in the rehabilitation process in Honduras, with the first planting of new banana fields at Mendez Farm, Barimasa Zone on May 4, followed closely with planting at Copote Farm in the Isletas Zone and most recently the Palo Verde farm in the Coyoles Zone.

As the company works to restore production volumes derived from these devastated areas in Honduras and Guatemala, Dole expects customers will begin receiving Dole premium fruit from these regions in January 2022.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye